GNMX - Aevi Genomic Medicine, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Aevi Genomic Medicine, Inc.

435 Devon Park Drive
Suite 715
Wayne, PA 19087
United States

Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael F. ColaCEO, Pres & Director491.99kN/A1960
Dr. Garry A. NeilChief Scientific Officer428.38kN/A1954
Mr. Michael McInawCFO & ControllerN/AN/A1987
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidate is AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, a monoclonal antibody, which is in preclinical research program for the treatment of auto-immune pediatric disease. In addition, it focuses on evaluating the anti-seizure activity of AEVI-004 in a preclinical model as part of the National Institutes of Health Epilepsy Treatment Screening Program. It has a development and option agreement with Kyowa Hakko Kirin Co., Ltd. related to AEVI-002 and AEVI-005. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Corporate Governance

Aevi Genomic Medicine, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.